Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

被引：76

作者：

Gerson, James N. ^{[1
]}

Handorf, Elizabeth ^{[1
]}

Villa, Diego ^{[2
]}

Gerrie, Alina S. ^{[2
]}

Chapani, Pary ^{[2
]}

Li, Shaoying ^{[3
]}

Medeiros, L. Jeffrey ^{[3
]}

Wang, Michael, I ^{[3
]}

Cohen, Jonathon B. ^{[4
]}

Calzada, Oscar ^{[4
]}

Churnetski, Michael C. ^{[4
]}

Hill, Brian T. ^{[5
]}

Sawalha, Yazeed ^{[5
]}

Hernandez-Ilizaliturri, Francisco J. ^{[6
]}

Kothari, Shalin ^{[6
]}

Vose, Julie M. ^{[7
]}

Bast, Martin A. ^{[7
]}

Fenske, Timothy S. ^{[8
]}

Gari, Swapna Narayana Rao ^{[8
]}

Maddocks, Kami J. ^{[9
]}

Bond, David ^{[9
]}

Bachanova, Veronika ^{[10
]}

Kolla, Bhaskar ^{[10
]}

Chavez, Julio ^{[11
]}

Shah, Bijal ^{[11
]}

Lansigan, Frederick ^{[12
]}

Burns, Timothy F. ^{[12
]}

Donovan, Alexandra M. ^{[12
]}

Wagner-Johnston, Nina ^{[13
]}

Messmer, Marcus ^{[13
]}

Mehta, Amitkumar ^{[14
]}

Anderson, Jennifer K. ^{[14
]}

Reddy, Nishitha ^{[15
]}

Kovach, Alexandra E. ^{[15
]}

Landsburg, Daniel J. ^{[16
]}

Glenn, Martha ^{[17
]}

Inwards, David J. ^{[18
]}

Karmali, Reem ^{[19
]}

Kaplan, Jason B. ^{[19
]}

Caimi, Paolo F. ^{[20
]}

Rajguru, Saurabh ^{[21
]}

Evens, Andrew ^{[22
]}

Klein, Andreas ^{[22
]}

Umyarova, Elvira ^{[23
]}

Pulluri, Bhargavi ^{[23
]}

Amengual, Jennifer E. ^{[24
]}

Lue, Jennifer K. ^{[24
]}

Diefenbach, Catherine ^{[25
]}

Fisher, Richard, I ^{[1
]}

Barta, Stefan K. ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] BC Canc, Vancouver, BC, Canada

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[7] Univ Nebraska, Canc Ctr, Omaha, NE 68182 USA

[8] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[9] Ohio State Univ, Columbus, OH 43210 USA

[10] Univ Minnesota, Minneapolis, MN USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[13] Johns Hopkins Univ, Baltimore, MD USA

[14] Univ Alabama Birmingham, Canc Ctr, Birmingham, AL USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[17] Huntsman Canc Inst, Salt Lake City, UT USA

[18] Mayo Clin, Rochester, MN USA

[19] Northwestern Univ, Evanston, IL USA

[20] Case Western Reserve Univ, Cleveland, OH 44106 USA

[21] Univ Wisconsin, Madison, WI USA

[22] Tufts Univ, Boston, MA 02111 USA

[23] Univ Vermont, Burlington, VT USA

[24] Columbia Univ, New York, NY USA

[25] NYU, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 06期

关键词：

PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; RANDOMIZED-TRIALS; TRANSPLANTATION; IMMUNOCHEMOTHERAPY; PATHOGENESIS; MULTICENTER; THERAPY; PATTERN; IMPACT;

D O I：

10.1200/JCO.18.00690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEMantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.PATIENTS AND METHODSWe retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.RESULTSData were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).CONCLUSIONIn this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

引用

页码：471 / +

页数：17

共 50 条

[21] Autologous transplantation and management of younger patients with mantle cell lymphoma
Geisler, Christian H.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2012, 25 (02) : 211 - 220
[22] Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma
Guy, Daniel
Kahl, Brad S.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (05) : 861 - 870
[23] Is rituximab retro in mantle cell lymphoma?
Ryan, Christine E.
Cohen, Jonathon B.
BLOOD, 2024, 144 (03) : 241 - 243
[24] Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
Rivas-Delgado, Alfredo
Magnano, Laura
Moreno-Velazquez, Miriam
Garcia, Olga
Nadeu, Ferran
Mozas, Pablo
Dlouhy, Ivan
Baumann, Tycho
Rovira, Jordina
Gonzalez-Farre, Blanca
Martinez, Antonio
Balague, Olga
Delgado, Julio
Villamor, Neus
Gine, Eva
Campo, Elias
Sancho-Cia, Juan M.
Lopez-Guillermo, Armando
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (05) : 753 - 759
[25] The effect of Rituximab on patients with follicular and mantle-cell lymphoma
Ghielmini, M
Schmitz, SFH
Bürki, K
Pichert, G
Betticher, DC
Stupp, R
Wernli, M
Lohri, A
Schmitter, D
Bertoni, F
Cerny, T
ANNALS OF ONCOLOGY, 2000, 11 : 123 - 126
[26] Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma
Graf, Solomon A.
Stevenson, Philip A.
Holmberg, Leona A.
Till, Brian G.
Press, Oliver W.
Chauncey, Thomas R.
Smith, Stephen D.
Philip, Mary
Orozco, Johnnie J.
Shustov, Andrei R.
Green, Damian J.
Libby, Edward N.
Bensinger, William I.
Pagel, John M.
Maloney, David G.
Zhou, Yi
Cassaday, Ryan D.
Gopal, Ajay K.
BLOOD, 2014, 124 (21)
[27] RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP
Le Gouill, S.
Thieblemont, C.
Oberic, L.
Moreau, A.
Nouabdallah, K.
Gyan, E.
Damaj, G.
Ribrag, V.
Feugier, P.
Casasnovas, O.
Zerazhi, H.
Haioun, C.
Tilly, H.
Tournilhac, O.
Maisonneuve, H.
Le Du, K.
Fornecker, L. M.
Van Den Neste, E.
Canioni, D.
Salles, G.
De La Chapelle, T. Lamy
Bene, M-C
Gressin, R.
Hermine, O.
HAEMATOLOGICA, 2017, 102 : 4 - 4
[28] Postibrutinib outcomes in patients with mantle cell lymphoma
Martin, Peter
Maddocks, Kami
Leonard, John P.
Ruan, Jia
Goy, Andre
Wagner-Johnston, Nina
Rule, Simon
Advani, Ranjana
Iberri, David
Phillips, Tycel
Spurgeon, Stephen
Kozin, Eliana
Noto, Katherine
Chen, Zhengming
Jurczak, Wojciech
Auer, Rebecca
Chmielowska, Ewa
Stilgenbauer, Stephan
Bloehdorn, Johannes
Portell, Craig
Williams, Michael E.
Dreyling, Martin
Barr, Paul M.
Chen-Kiang, Selina
DiLiberto, Maurizio
Furman, Richard R.
Blum, Kristie A.
BLOOD, 2016, 127 (12) : 1559 - 1563
[29] Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients
Joshi, Komal
Hubbard, Richard
Bishton, Mark J.
HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 604 - 606
[30] Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma
Fu, Shuangshuang
Wang, Michael
Zhao, Hui
Li, Ruosha
Lairson, David
Giordano, Sharon
Zhao, Bo
Du, Xianglin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S273 - S274

← 1 2 3 4 5 →